PCRX Stock Overview
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States.
Pacira BioSciences Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$63.43|
|52 Week High||US$80.00|
|52 Week Low||US$45.05|
|1 Month Change||5.12%|
|3 Month Change||20.57%|
|1 Year Change||-6.53%|
|3 Year Change||63.23%|
|5 Year Change||70.28%|
|Change since IPO||803.56%|
Recent News & Updates
Pacira BioSciences: Higher Prices On The Horizon
The company reports an EPS beat of $0.72 in the third quarter. We look into how management has been employing its capital. We like the results as well as the underlying trend. A bullish move through a breakout above the bullish triangle (below) could be on the cards here shortly.
Investors Appear Satisfied With Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Prospects
With a price-to-earnings (or "P/E") ratio of 37.3x Pacira BioSciences, Inc. ( NASDAQ:PCRX ) may be sending very bearish...
|PCRX||US Pharmaceuticals||US Market|
Return vs Industry: PCRX underperformed the US Pharmaceuticals industry which returned 7.1% over the past year.
Return vs Market: PCRX underperformed the US Market which returned 6.6% over the past year.
|PCRX Average Weekly Movement||4.5%|
|Pharmaceuticals Industry Average Movement||10.5%|
|Market Average Movement||6.7%|
|10% most volatile stocks in US Market||15.6%|
|10% least volatile stocks in US Market||2.4%|
Stable Share Price: PCRX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: PCRX's weekly volatility (5%) has been stable over the past year.
About the Company
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States. The company develops products based on its proprietary DepoFoam product delivery technology that encapsulates drugs without altering their molecular structure. It offers EXPAREL, a bupivacaine liposome injectable suspension, administered at the time of surgery to control pain and reduce or eliminate the use of opioids for acute postsurgical pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature only to targeted nerves.
Pacira BioSciences Fundamentals Summary
|PCRX fundamental statistics|
Is PCRX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|PCRX income statement (TTM)|
|Cost of Revenue||US$191.91m|
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
|Earnings per share (EPS)||1.38|
|Net Profit Margin||12.01%|
How did PCRX perform over the long term?See historical performance and comparison
Is Pacira BioSciences undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: PCRX ($63.43) is trading below our estimate of fair value ($317.69)
Significantly Below Fair Value: PCRX is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: PCRX is poor value based on its PE Ratio (45.8x) compared to the US Pharmaceuticals industry average (23.3x).
PE vs Market: PCRX is poor value based on its PE Ratio (45.8x) compared to the US market (16.7x).
Price to Earnings Growth Ratio
PEG Ratio: PCRX is poor value based on its PEG Ratio (1.4x)
Price to Book Ratio
PB vs Industry: PCRX is overvalued based on its PB Ratio (3.9x) compared to the US Pharmaceuticals industry average (2.2x).
How is Pacira BioSciences forecast to perform in the next 1 to 3 years based on estimates from 11 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PCRX's forecast earnings growth (32% per year) is above the savings rate (2%).
Earnings vs Market: PCRX's earnings (32% per year) are forecast to grow faster than the US market (13.1% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: PCRX's revenue (16.6% per year) is forecast to grow faster than the US market (9.2% per year).
High Growth Revenue: PCRX's revenue (16.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: PCRX's Return on Equity is forecast to be high in 3 years time (23.6%)
How has Pacira BioSciences performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: PCRX has high quality earnings.
Growing Profit Margin: PCRX's current net profit margins (12%) are lower than last year (30%).
Past Earnings Growth Analysis
Earnings Trend: PCRX has become profitable over the past 5 years, growing earnings by 78% per year.
Accelerating Growth: PCRX's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: PCRX had negative earnings growth (-51.1%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (12.2%).
Return on Equity
High ROE: PCRX's Return on Equity (8.6%) is considered low.
How is Pacira BioSciences's financial position?
Financial Position Analysis
Short Term Liabilities: PCRX's short term assets ($822.4M) exceed its short term liabilities ($225.8M).
Long Term Liabilities: PCRX's short term assets ($822.4M) exceed its long term liabilities ($411.6M).
Debt to Equity History and Analysis
Debt Level: PCRX has more cash than its total debt.
Reducing Debt: PCRX's debt to equity ratio has increased from 50.2% to 67.1% over the past 5 years.
Debt Coverage: PCRX's debt is well covered by operating cash flow (31%).
Interest Coverage: PCRX's interest payments on its debt are well covered by EBIT (4.3x coverage).
What is Pacira BioSciences's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate PCRX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate PCRX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if PCRX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if PCRX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of PCRX's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Dave Stack (71 yo)
Mr. David M. Stack, also known as Dave, has been the Chief Executive Officer of Pacira Pharmaceuticals Inc. Since November 2007, Mr. Stack serves as Director of CODA Biotherapeutics Inc. since December 202...
CEO Compensation Analysis
Compensation vs Market: Dave's total compensation ($USD9.34M) is above average for companies of similar size in the US market ($USD5.23M).
Compensation vs Earnings: Dave's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.
Experienced Management: PCRX's management team is seasoned and experienced (5.7 years average tenure).
Experienced Board: PCRX's board of directors are seasoned and experienced ( 10.6 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.5%.
Pacira BioSciences, Inc.'s employee growth, exchange listings and data sources
- Name: Pacira BioSciences, Inc.
- Ticker: PCRX
- Exchange: NasdaqGS
- Founded: 2006
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$2.825b
- Shares outstanding: 44.54m
- Website: https://www.pacira.com
Number of Employees
- Pacira BioSciences, Inc.
- 5 Sylvan Way
- Suite 300
- New Jersey
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/01/21 23:33|
|End of Day Share Price||2022/01/21 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.